Planview Acquires Sciforma, Expanding Global Leadership in Portfolio Management Solutions
Planview®, the leading platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced it has completed its acquisition of Sciforma, a prominent provider of Project Portfolio Management (PPM) and Product Development solutions. This strategic acquisition further solidifies Planview's position as the undisputed leader in enterprise portfolio management, bringing market-leading solutions to organizations at every PPM maturity level.
"By acquiring Sciforma, we're strengthening our commitment to portfolio management practitioners worldwide," said Razat Gaurav, CEO of Planview. "Together, we're building the world's largest community of portfolio and product development professionals, delivering enterprise solutions that address their most critical challenges. No one in the market is better equipped to guide organizations through every stage of their portfolio management evolution."
This acquisition strengthens Planview's presence in Europe, where Sciforma has built a strong market position. Customers can expect seamless continuity of service from Sciforma's customer-facing teams, now enhanced by Planview's global customer success organization. The combined company offers unprecedented regional coverage and a complete spectrum of solutions that support organizations at every stage of PPM maturity – from early adoption to sophisticated enterprise implementations – enabling customers to evolve and grow with confidence.
"We're thrilled to join Planview, marking an exciting new chapter for both Sciforma customers and employees," said Doug A. Braun, Sciforma CEO. "Our shared values and commitment to customer success create a natural cultural fit, while Planview's global resources and market leadership will amplify our capabilities worldwide. With access to Planview's extensive customer success organization and expanded market reach, we'll accelerate innovation and deliver even greater value to our customers."
Sciforma's existing customers will continue to be able to use their products as they do today, now backed by Planview's extensive resources and expertise. Planview customers can expect flexibility and ease of integration by selecting the solutions that work best for their organization, now including Sciforma's world-class offerings in PPM and PD.
Ropes & Gray and Gides Loyrette Nouel LLP served as lead legal counsel. DLA Piper served as legal counsel for Sciforma.
To learn more about Planview's portfolio management solutions, visit www.planview.com.
About Planview
Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), giving its customers the strategic foresight to prioritize investments and initiatives, make those plans real within constraints, and pivot with certainty when things change. Our connected platform of solutions underpins the business and digital transformations of more than 2.7 million users globally, including 45 of the Fortune 100. Headquartered in Austin, Texas, Planview has over 1,300 employees worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218853981/en/
Contacts
Media Contact
Leslie Marcotte
Senior Director, Corporate Marketing
lmarcotte@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Unveils New Post-Hoc Analyses of LIBERTY Studies at the 20 th ECCO Congress Further Evaluating the Efficacy and Safety of Subcutaneous (SC) Infliximab20.2.2025 18:45:00 EET | Press release
Celltrion announced new post-hoc analyses of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), at the 20th European Crohn’s and Colitis Organisation (ECCO) Congress showcasing the treatment’s effectiveness across a range of key clinical outcomes in inflammatory bowel disease (IBD). The analyses highlight Celltrion’s ongoing efforts to evaluate the efficacy and safety of subcutaneous (SC) infliximab (CT-P13 SC) in achieving endoscopic-histologic remission in ulcerative colitis (UC), clinical and endoscopic improvement across all disease locations in Crohn’s disease (CD), and supporting early clinical recapture after dose escalation following loss of response in CD and UC, and long-term drug persistence regardless of ADA in CD patients.3,4,5,6 LIBERTY-UC Phase III Post-Hoc Analysis (LIBERTY-UC Endo-Histological Outcome) A post-hoc analysis of the Phase 3 LIBERTY-UC study showed that maintenance therapy with SC infliximab resulted in significantly greater improvements in endoscopic
NTT DATA Launches Smart AI Agent ™ to Accelerate Generative AI Adoption and Drive $2 Billion in Revenue by 202720.2.2025 17:33:00 EET | Press release
NTT DATA, a global digital business and IT services leader, today announced the international launch of its next-generation Smart AI Agent™. This advanced AI tool is a cornerstone of the company’s strategy to accelerate the adoption of Generative AI, with an estimated $2 billion in revenue that we aim to achieve from Smart AI Agent™-related business by 2027. The Smart AI Agent™ autonomously extracts, organizes, and executes tasks in response to user instructions, complementing existing workforces and streamlining time-consuming processes. By enhancing efficiency across industries, the Smart AI Agent™ enables businesses to rapidly evaluate and deploy Generative AI applications, optimizing workflows and driving greater productivity. Yutaka Sasaki, President and CEO, NTT DATA, said: “The launch of our Smart AI Agent™ is a direct response to the growing demand for tools that unlock the full potential of Generative AI. At NTT DATA, we’re committed to pioneering innovation that drives enterp
New global guideline published on managing fungal infections caused by Candida20.2.2025 17:15:00 EET | Press release
A new global guideline for the diagnosis and treatment of Candidainfections was recently published in Lancet Infectious Diseases1. This guideline sets out new standards for managing fungal infections, which affect millions of people worldwide every year. The global guideline was developed by a team of more than 100 experts spanning 35 countries and led by Professor Dr. Oliver A. Cornely and Dr. Rosanne Sprute from University Hospital Cologne. One year following the European Medical Association (EMA)2 approval, rezafungin ▼3 has been included in the guideline, along with other echinocandins, as a strongly recommended first line therapy option for the treatment of candidaemia. Echinocandins, including rezafungin, are preferred for all forms of invasive candidiasis, excluding CNS and ocular infections, due to their broad antifungal activity and favourable safety profile. The new guideline, which took four years to develop, contains recommendations for clinicians on the prevention, diagnos
SiMa.ai and HTEC Strengthen Strategic Partnership to Advance Premium ML System-on-Chip Solutions20.2.2025 17:08:00 EET | Press release
HTEC, a global digital engineering services firm, is pleased to announce a partnership extension with SiMa.ai, the software-centric, embedded edge machine learning system-on-chip (MLSoC) company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220864540/en/ HTEC announces partnership extension with SiMa.ai, an embedded edge machine learning system-on-chip company. (Graphic: Business Wire) During a successful five-year collaboration, SiMa.ai and HTEC built an ML compiler, system drivers, and other complex AI-powered software tools to support SiMa.ai’s edge AI platform. SiMa.ai also leveraged HTEC’s AI- and ML-driven engineering and chip optimization expertise to enhance its purpose-built MLSoC™. Now, HTEC will support SiMa.ai’s strategic initiatives and help streamline the delivery of SiMa.ai solutions built on its cutting-edge ONE Platform for Edge AI, further enhancing the company’s hardware and software. “Collaborating w
ClickHouse Announces BYOC (Bring Your Own Cloud) on AWS20.2.2025 16:00:00 EET | Press release
As enterprises look to modernize and adopt cloud-native architectures, they must still comply with existing security mandates and geographic regulations. This becomes especially challenging with cloud-based database services, where any data leaving the enterprise Virtual Private Cloud (VPC) requires thorough security review. These considerations are critical for organizations in regulated industries or those handling sensitive customer data. ClickHouse BYOC was built to address this very challenge. It allows organizations to adopt unique capabilities of the fully-managed ClickHouse Cloud service, a leading real-time analytical database, while maintaining full ownership and control of their data within their VPC. In ClickHouse BYOC architecture, the data plane consisting of storage and compute resources resides in the customer VPC, which ensures that customers are able to adhere to data residency and governance requirements, while offloading operational complexities of managing ClickHou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom